Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P36
Within normal range
vs 5Y Ago
-8.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -20.10% |
| Q3 2025 | 20.29% |
| Q2 2025 | -13.58% |
| Q1 2025 | -10.20% |
| Q4 2024 | -26.44% |
| Q3 2024 | 52.74% |
| Q2 2024 | -118.09% |
| Q1 2024 | 8.04% |
| Q4 2023 | 10.29% |
| Q3 2023 | -107.88% |
| Q2 2023 | 5.62% |
| Q1 2023 | 2.79% |
| Q4 2022 | -20.39% |
| Q3 2022 | 27.11% |
| Q2 2022 | 21.28% |
| Q1 2022 | -36.30% |
| Q4 2021 | -13.34% |
| Q3 2021 | -916.52% |
| Q2 2021 | 110.66% |
| Q1 2021 | -14.00% |
| Q4 2020 | 2.30% |
| Q3 2020 | 9.67% |
| Q2 2020 | 10.51% |
| Q1 2020 | -33.14% |
| Q4 2019 | 5.31% |
| Q3 2019 | -5.04% |
| Q2 2019 | -3.64% |
| Q1 2019 | -119.54% |
| Q4 2018 | 15.31% |
| Q3 2018 | 5.99% |
| Q2 2018 | -21.44% |
| Q1 2018 | -26.80% |
| Q4 2017 | 20.29% |
| Q3 2017 | -24.00% |
| Q2 2017 | -9.39% |
| Q1 2017 | -24.73% |
| Q4 2016 | 25.75% |
| Q3 2016 | -26.62% |
| Q2 2016 | -16.15% |
| Q1 2016 | -378.75% |